Skip to content
Triangle logo TriangleGet started
← Neuroblastoma

HEALTH PROFESSIONAL · SOURCE READING

Locoregional recurrence

Source: Neuroblastoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: April 28, 2025 · Captured 2026-09-09.

Selected source text with whitespace normalised. This Triangle page is not an NCI PDQ summary.

Context: Treatment of Recurrent or Refractory Neuroblastoma / Recurrent Neuroblastoma in Patients Initially Classified as Intermediate Risk

Treatment options for locoregional recurrent neuroblastoma initially classified as intermediate risk include the following:

Surgery (complete resection).

Surgery (incomplete resection) followed by chemotherapy.

Radiation therapy. Radiation therapy is considered only for patients with disease progression after chemotherapy and second-look surgery.[16]

Source links and citations

Locoregional recurrence of neuroblastoma with favorable biology that occurs more than 3 months after completion of chemotherapy may be treated surgically. If resection is less than near total, then additional chemotherapy may be given. Chemotherapy should be selected based on the previous chemotherapy received.[16]

Source links and citations

Publication references

Read the original reference and check its publication notices.

Preserved source evidence · Not medical advice